What's different about this vaccine is the way that response is being created. Instead of introducing a weakened version of the herpes virus or protein subunit, this vaccine uses a small section of DNA to produce T-cells and stimulate the immune response.[50] The new vaccine candidate is designed to prevent new infections, and to treat those who already have the infection. In February 2014, it was announced that Frazer's vaccine against genital herpes passed human safety trials in a trial of 20 Australians.[51] In October 2014, Admedus announced success in creating a positive T-cell response in 95% of participants.[52] Further research is required to determine if the vaccine can prevent transmission.